These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

110 related items for PubMed ID: 11422164

  • 21. Immunization of healthy adult subjects in the United States with inactivated Mycobacterium vaccae administered in a three-dose series.
    von Reyn CF, Arbeit RD, Yeaman G, Waddell RD, Marsh BJ, Morin P, Modlin JF, Remold HG.
    Clin Infect Dis; 1997 May; 24(5):843-8. PubMed ID: 9142780
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension.
    van de Kerkhof PC, Segaert S, Lahfa M, Luger TA, Karolyi Z, Kaszuba A, Leigheb G, Camacho FM, Forsea D, Zang C, Boussuge MP, Paolozzi L, Wajdula J.
    Br J Dermatol; 2008 Nov; 159(5):1177-85. PubMed ID: 18673365
    [Abstract] [Full Text] [Related]

  • 24. Immunological consequences of three doses of heat-killed Mycobacterium vaccae in the immunotherapy of tuberculosis.
    Dlugovitzky D, Fiorenza G, Farroni M, Bogue C, Stanford C, Stanford J.
    Respir Med; 2006 Jun; 100(6):1079-87. PubMed ID: 16278080
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.
    Reich K, Armstrong AW, Foley P, Song M, Wasfi Y, Randazzo B, Li S, Shen YK, Gordon KB.
    J Am Acad Dermatol; 2017 Mar; 76(3):418-431. PubMed ID: 28057361
    [Abstract] [Full Text] [Related]

  • 28. [A clinical study on vaccine of Mycobacterium vaccae in treating pulmonary tuberculosis].
    Wang W, Jin G, Ye Y, Xia X, Wang A, Zhuang Y, Li G, Sun H, Wang Z, Lin M, Chen H, Li J, Dan Z, Zhang X.
    Zhonghua Jie He He Hu Xi Za Zhi; 1999 Feb; 22(2):108-10. PubMed ID: 11820954
    [Abstract] [Full Text] [Related]

  • 29. Immunotherapy with Mycobacterium vaccae in the treatment of tuberculosis.
    Stanford J, Stanford C, Grange J.
    Front Biosci; 2004 May 01; 9():1701-19. PubMed ID: 14977580
    [Abstract] [Full Text] [Related]

  • 30. Immunization of HIV-infected adults with a three-dose series of inactivated Mycobacterium vaccae.
    Marsh BJ, Fordham von Reyn C, Arbeit RD, Morin P.
    Am J Med Sci; 1997 Jun 01; 313(6):377-83. PubMed ID: 9186154
    [Abstract] [Full Text] [Related]

  • 31. Chinese herbal Pulian ointment in treating psoriasis vulgaris of blood-heat syndrome: a multi-center, double-blind, randomized, placebo-controlled trial.
    Li N, Zhao W, Xing J, Liu J, Zhang G, Zhang Y, Li Y, Liu W, Shi F, Bai Y.
    BMC Complement Altern Med; 2017 May 15; 17(1):264. PubMed ID: 28506228
    [Abstract] [Full Text] [Related]

  • 32. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.
    Thaçi D, Blauvelt A, Reich K, Tsai TF, Vanaclocha F, Kingo K, Ziv M, Pinter A, Hugot S, You R, Milutinovic M.
    J Am Acad Dermatol; 2015 Sep 15; 73(3):400-9. PubMed ID: 26092291
    [Abstract] [Full Text] [Related]

  • 33. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study.
    Rich P, Sigurgeirsson B, Thaci D, Ortonne JP, Paul C, Schopf RE, Morita A, Roseau K, Harfst E, Guettner A, Machacek M, Papavassilis C.
    Br J Dermatol; 2013 Feb 15; 168(2):402-11. PubMed ID: 23362969
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Clinical Experience Acquired with Raptiva (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from extended treatment in an international, Phase III, placebo-controlled trial.
    Sterry W, Stingl G, Langley RG, Zacharie H, Lahfa M, Giannetti A, Ferrándiz C, Sinclair R, Saurat JH, CLEAR Multinational Study Group.
    J Dtsch Dermatol Ges; 2006 Nov 15; 4(11):947-56. PubMed ID: 17081270
    [Abstract] [Full Text] [Related]

  • 36. Randomised trial of intradermal Mycobacterium vaccae or intradermal hepatitis B immunisation in children with HIV infection.
    Johnson D, Waddell RD, Pelton SI, Jaeger AS, Modlin JF, Yogev R, Morin P, Arbeit RD, von Reyn CF.
    Vaccine; 1999 Jun 04; 17(20-21):2583-7. PubMed ID: 10418906
    [Abstract] [Full Text] [Related]

  • 37. An open-label study of alefacept plus ultraviolet B light as combination therapy for chronic plaque psoriasis.
    Ortonne JP, Khemis A, Koo JY, Choi J.
    J Eur Acad Dermatol Venereol; 2005 Sep 04; 19(5):556-63. PubMed ID: 16164708
    [Abstract] [Full Text] [Related]

  • 38. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
    Spuls PI, Hooft L.
    Br J Dermatol; 2012 Oct 04; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
    [Abstract] [Full Text] [Related]

  • 39. Efficacy and tolerability of a cosmetically acceptable coal tar solution in the treatment of moderate plaque psoriasis: a controlled comparison with calcipotriene (calcipotriol) cream.
    Alora-Palli MB, Perkins AC, Van Cott A, Kimball AB.
    Am J Clin Dermatol; 2010 Oct 04; 11(4):275-83. PubMed ID: 20513160
    [Abstract] [Full Text] [Related]

  • 40. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction.
    Papp KA, Tyring S, Lahfa M, Prinz J, Griffiths CE, Nakanishi AM, Zitnik R, van de Kerkhof PC, Melvin L, Etanercept Psoriasis Study Group.
    Br J Dermatol; 2005 Jun 04; 152(6):1304-12. PubMed ID: 15948997
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.